icon-folder.gif   Conference Reports for NATAP  
 
  5th International Workshop on Hepatitis C
Resistance and New Compounds
24-25 June 2010, Boston, MA USA
Back grey_arrow_rt.gif
 
 
 
Telaprevir/Peginterferon/Ribavirin
 
 
  Reported by Jules Levin
5th International Workshop on Hepatitis C, Resistance and New Compounds
June24-25, 2010, Boston MA
 
Tara L Kieffer, DJ Bartels, JC Sullivan, EZ Zhang, AM Tigges, JL Dorrian, and AD Kwong, Vertex Pharmaceuticals Incorporated, Cambridge MA, USA
 
"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"

1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hézode C, et al. N Engl J Med 2009;360:1839-1850

1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hézode C, et al. N Engl J Med 2009;360:1839-1850;
3McHutchison JG, et al. N EnglJ Med 2010; 362:1292-1303; 4Shiffman ML, et al. Hepatology 2008;48 (Suppl 4):1135A

"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"